Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate

BACKGROUND: Bispecific antibodies redirecting T cells to the tumor obtain increasing interest as potential cancer immunotherapy. ERY974, a full-length bispecific antibody targeting CD3ε on T cells and glypican 3 (GPC3) on tumors, has been in clinical development However, information on the influence...

Descripción completa

Detalles Bibliográficos
Autores principales: Waaijer, Stijn JH, Giesen, Danique, Ishiguro, Takahiro, Sano, Yuji, Sugaya, Naofumi, Schröder, Carolina P, de Vries, Elisabeth GE, Lub-de Hooge, Marjolijn N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206965/
https://www.ncbi.nlm.nih.gov/pubmed/32217763
http://dx.doi.org/10.1136/jitc-2020-000548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206965/
https://www.ncbi.nlm.nih.gov/pubmed/32217763
http://dx.doi.org/10.1136/jitc-2020-000548

Ejemplares similares